RxDoctor Payments Data

Priyanka Gupta, MD

Allergy/ Immunology · New Braunfels, TXNPI 1346281839

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $164,770 of the $207,301 with a category attached, or 79.5%. AstraZeneca accounts for 72.5% of it on its own, with 44 other manufacturers making up the rest. 2025 is the largest year on record at $64,255, 3.6 times the $17,747 reported in 2019.

$207,301in general payments, 2019–2025

Across 674 payments — averaging $307.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$150K
  • Optinose US, Inc.$49K
  • GSK$1K
  • CSL Behring$669
  • Kaleo, Inc.$558
  • Regeneron Healthcare Solutions, Inc.$514
  • plus $5K from 39 others

What the payments were for

  • Consulting fees$2,4651%
  • Speaking & faculty fees$164,77079%
  • Travel & lodging$24,41712%
  • Food & beverage$15,5838%
  • Education$660%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy/ immunology providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,056,711
Medicare patients
617
Services billed
39,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter167$132,508
Arnuity ElliptaFluticasone Furoate76$26,411
Breo ElliptaFluticasone/Vilanterol47$25,783
Azelastine Hcl613$18,282
Advair HfaFluticasone Propion/Salmeterol35$13,640
Epinephrine50$12,010
Fluticasone-SalmeterolFluticasone Propion/Salmeterol90$10,848
Fluticasone Propionate607$8,200
Azelastine-FluticasoneAzelastine/Fluticasone76$7,872
Qvar RedihalerBeclomethasone Dipropionate25$6,312
Mometasone Furoate69$5,452
Fluticasone Propionate HfaFluticasone Propionate23$5,380
Montelukast Sodium789$5,335
Albuterol Sulfate HfaAlbuterol Sulfate170$4,881
Olopatadine Hcl43$4,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta$1,058$184,701290 claims
Hikma Pharmaceuticals USAEpinephrine$88$12,01050 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$201$6,31225 claims
AstraZenecaPulmicort Flexhaler$150,196$2,96313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Texason file to place this against a meaningful peer group, so we don't.

Other allergy/ immunology in New Braunfels

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →